The Top 5 Biosimilar Articles for the Week of May 19

Number 5: Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs and expanding treatment access.

Number 4: Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.

Number 3: Sarfaraz K. Niazi, PhD, asserts that India's recently revised 2025 biosimilar guidelines represent a significant and rational step towards global regulatory alignment by deemphasizing animal and human efficacy testing in favor of scientifically robust, risk-based, and ethically sound frameworks.

Number 2: While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.

Number 1: Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

To read all of these articles and more, visit centerforbiosimilars.com.